Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Ionis Pharmaceuticals EVP and Chief Business Officer Joseph Baroldi reported indirect spouse transactions in Ionis common stock. On June 26, 2026, Baroldi’s spouse exercised options for a total of 5,635 shares of common stock at exercise prices of $32.60 and $56.78 per share and then sold 5,635 shares in an open-market transaction at a weighted average price of $80.1595 per share under a pre-arranged Rule 10b5-1 Trading Plan. Following these transactions, Baroldi holds 48,522 shares directly, and his spouse holds 4,669 shares indirectly attributable to him.
IONIS PHARMACEUTICALS INC executive Patrick R. O’Neil sold 3,069 shares of common stock in an open-market transaction. The shares were sold at $80.00 per share, and he now directly holds 61,470 shares following the sale.
The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, which typically means it was scheduled in advance rather than timed discretionarily.
Ionis Pharmaceuticals executive Eugene Schneider reported an exercise-and-sale transaction in company stock. On June 26, 2026, he exercised options to acquire 26,000 shares of common stock at $60.89 per share, then sold 26,000 shares in open-market trades at a weighted-average price of $81.046 per share.
The sales were executed under a pre-arranged Rule 10b5-1 Trading Plan adopted on November 19, 2025. After these transactions, Schneider directly held 77,114 shares of Ionis common stock.
Ionis Pharmaceuticals CEO Brett P. Monia reported a series of option exercises paired with open-market sales of common stock. Over June 24–26, 2026, he exercised options covering 85,637 shares and sold the same number of shares in the market, a net disposition.
Sales included 50,000 shares at a weighted average price of $80.59, 21,072 shares at $78.49, and 14,565 shares at $78.4128. The filing states these sales were made pursuant to a Rule 10b5-1 Trading Plan. After the transactions, he directly holds 245,571 shares of common stock and 99,872 non-qualified stock options.
Ionis Pharmaceuticals EVP Research Eric Swayze reported an open-market sale of company stock. On June 25, 2026, he sold 10,602 shares of Common Stock at a weighted average price of $79.1824 per share in a transaction coded as an open-market sale.
The sale was executed under a Rule 10b5-1 trading plan adopted on March 6, 2026, indicating it was pre-arranged rather than opportunistic. Following the sale, Swayze directly held 21,759 shares of Ionis Pharmaceuticals common stock, and an additional 318 shares were reported as indirectly owned through his son.
IONS submitted a Form 144 notice reporting a proposed sale of 5,635 shares of Common Stock with an aggregate value of $451,699.00. The filing lists 165,262,556 shares outstanding as of 06/26/2026 and names Stifel Nicolaus & Company as the broker. The notice also records two cash stock option exercises dated 06/26/2026 for 3,866 and 1,769 shares.
IONS submitted a Form 144 proposing the sale of 47,884 shares of Common Stock with an aggregate value of $3,880,807.00. The filing lists 165,262,556 shares outstanding as of 06/26/2026 and names Stifel Nicolaus & Company Inc as broker. The shares trace to prior stock option exercises on 01/02/2020 (26,000 shares) and 01/04/2021 (21,884 shares).
IONS filed a Form 144 notice reporting proposed sales of Common Stock tied to restricted equity awards. The notice lists specific grant dates and share counts for restricted stock: 3,110 (01/15/2022), 1,861 (01/15/2021), 1,956 (01/15/2023), 1,900 (02/23/2023) and 1,775 (02/01/2024).